These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 17315053)
41. Atorvastatin improves the response to sildenafil in hypercholesterolemic men with erectile dysfunction not initially responsive to sildenafil. Dadkhah F; Safarinejad MR; Asgari MA; Hosseini SY; Lashay A; Amini E Int J Impot Res; 2010; 22(1):51-60. PubMed ID: 19865092 [TBL] [Abstract][Full Text] [Related]
42. [New medications for treatment of erectile dysfunction]. Nagai A; Kumon H Nihon Rinsho; 2002 Jun; 60 Suppl 6():461-4. PubMed ID: 12166201 [No Abstract] [Full Text] [Related]
43. Sexual Dysfunction, Cardiovascular Risk and Effects of Pharmacotherapy. Imprialos KP; Stavropoulos K; Doumas M; Tziomalos K; Karagiannis A; Athyros VG Curr Vasc Pharmacol; 2018 Jan; 16(2):130-142. PubMed ID: 28595561 [TBL] [Abstract][Full Text] [Related]
44. Erection, erectile dysfunction: what has heart got to do with it? Khandheria BK Herz; 2003 Jun; 28(4):275-6. PubMed ID: 12916517 [No Abstract] [Full Text] [Related]
45. [Sexual activity and the heart]. Stein R; Hohmann CB Arq Bras Cardiol; 2006 Jan; 86(1):61-7. PubMed ID: 16491211 [No Abstract] [Full Text] [Related]
46. [Pharmacological therapy in erectile dysfunction--current standards and new viewpoint]. Schultheiss D; Stief CG; Truss MC; Jonas U Wien Med Wochenschr; 1997; 147(4-5):102-4. PubMed ID: 9190765 [TBL] [Abstract][Full Text] [Related]
47. Treating erectile dysfunction when PDE5 inhibitors fail. McMahon CN; Smith CJ; Shabsigh R BMJ; 2006 Mar; 332(7541):589-92. PubMed ID: 16528082 [No Abstract] [Full Text] [Related]
50. Diagnosis and management of erectile dysfunction in the primary care setting. Rosenberg MT Int J Clin Pract; 2007 Jul; 61(7):1198-208. PubMed ID: 17577299 [TBL] [Abstract][Full Text] [Related]
51. Atorvastatin improves erectile dysfunction in patients initially irresponsive to Sildenafil by the activation of endothelial nitric oxide synthase. El-Sisi AA; Hegazy SK; Salem KA; AbdElkawy KS Int J Impot Res; 2013; 25(4):143-8. PubMed ID: 23324897 [TBL] [Abstract][Full Text] [Related]
52. Phosphodiesterase type 5 inhibitors: state of the therapeutic class. Carson CC Urol Clin North Am; 2007 Nov; 34(4):507-15, vi. PubMed ID: 17983891 [TBL] [Abstract][Full Text] [Related]
54. The hemodynamics of erection and the pharmacotherapies of erectile dysfunction. Melman A; Christ GJ Heart Dis; 2002; 4(4):252-64. PubMed ID: 12147185 [TBL] [Abstract][Full Text] [Related]
55. How psychiatrists can build new therapies for impotence. Stahl SM J Clin Psychiatry; 1998 Feb; 59(2):47-8. PubMed ID: 9501884 [No Abstract] [Full Text] [Related]
56. Centrally acting mechanisms for the treatment of male sexual dysfunction. Miner MM; Seftel AD Urol Clin North Am; 2007 Nov; 34(4):483-96, v. PubMed ID: 17983889 [TBL] [Abstract][Full Text] [Related]
57. Testosterone therapy in erectile dysfunction and hypogonadism. Shabsigh R J Sex Med; 2005 Nov; 2(6):785-92. PubMed ID: 16422803 [TBL] [Abstract][Full Text] [Related]
58. Commentary on apomorphine versus sildenafil for erectile dysfunction. Carson CC J Urol; 2008 May; 179(5 Suppl):S95-6. PubMed ID: 18405768 [No Abstract] [Full Text] [Related]
59. Comparative effects of sildenafil, phentolamine, yohimbine and L-arginine on the rabbit corpus cavernosum. Sharabi FM; Daabees TT; El-Metwally MA; Senbel AM Fundam Clin Pharmacol; 2004 Apr; 18(2):187-94. PubMed ID: 15066133 [TBL] [Abstract][Full Text] [Related]
60. PDE5 inhibitors: is there more to come besides erectile dysfunction? Stief C Eur Urol; 2007 Oct; 52(4):943-4. PubMed ID: 17683851 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]